What is the level of liabilities of CureVac this year?
CureVac has a debt balance of 271.31 M EUR this year.
CureVac Liabilities 2025
CureVac Liabilities
271.31 M EUR
Ticker
CVAC
ISIN
NL0015436031
WKN
A2P71U
In 2025, CureVac's total liabilities amounted to 271.31 M EUR, a -17.08% difference from the 327.2 M EUR total liabilities in the previous year.
CureVac Aktienanalyse
What does CureVac do?
CureVac NV is a German biotechnology company that was founded in 2000 by Ingmar Hoerr, who still leads the company today. The company is headquartered in Tübingen and has a branch in Frankfurt am Main. CureVac's goal is to develop and produce innovative therapies to combat diseases. The history of CureVac began with a focus on the development of RNA-based therapeutics. RNA is a molecule that plays a central role in protein production within the cell. By using RNA in therapeutic applications, the body's own processes can be utilized to fight diseases. CureVac has successfully developed a variety of RNA-based therapeutics in recent years, which are in various stages of clinical development. CureVac's business model is based on providing its technology platform to other companies. These companies can use the platform to develop their own RNA-based therapeutics. CureVac receives fees for this service and also receives a share of any revenues resulting from these projects. CureVac also operates its own pipeline of therapeutic products based on various technologies. One important technology, for example, is the use of messenger RNA (mRNA) to produce proteins that can have a therapeutic effect. CureVac has entered into several partnerships with large pharmaceutical companies such as Sanofi and Boehringer Ingelheim to bring its products to market. The company benefits from the strength of its technology platform and its ability to develop new methods for the production of RNA-based therapeutics. Furthermore, CureVac has played an important role in containing the global COVID-19 pandemic. The company has developed an mRNA vaccine against the SARS-CoV-2 virus, which is approved in Europe. The vaccine has shown to be particularly effective and has a high efficacy against the various variants of the virus. CureVac has signed a contract with the European Union for the delivery of up to 405 million doses of its COVID-19 vaccine, making it an important partner in the fight against the pandemic. Overall, CureVac is a company with a strong focus on RNA-based therapeutics. The company has successfully built a strong technology platform in recent years, enabling other companies to develop their own RNA-based therapeutics. At the same time, CureVac has built its own pipeline of products in various stages of clinical development. The company benefits from the strength of its technology platform and its ability to develop sustainable and effective solutions for various diseases. The success of CureVac, particularly its role in the fight against the COVID-19 pandemic, has shown that RNA technology will play an important role in the future of biotechnology. CureVac ist eines der beliebtesten Unternehmen auf Eulerpool.com.Liabilities Details
Assessing CureVac's Liabilities
CureVac's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating CureVac's financial stability, operational efficiency, and long-term viability.
Year-to-Year Comparison
By comparing CureVac's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.
Impact on Investments
CureVac's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.
Interpreting Liability Fluctuations
Shifts in CureVac’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.
Frequently Asked Questions about CureVac stock
What were the liabilities of CureVac compared to the previous year?
The liabilities of CureVac have increased by -17.08% dropped compared to the previous year.
What are the consequences of high debt for investors of CureVac?
High liabilities can pose a risk for investors of CureVac, as they can weaken the company's financial position and impair its ability to meet its obligations.
What consequences do low liabilities have for investors in CureVac?
Low liabilities mean that CureVac has a strong financial position and is able to meet its obligations without overburdening its finances.
How does an increase in liabilities of CureVac affect the company?
An increase in liabilities of CureVac can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.
How does a reduction in the liabilities of CureVac affect the company?
A decrease in the liabilities of CureVac can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.
What are some factors that influence the liabilities of CureVac?
Some factors that can influence the liabilities of CureVac include investments, acquisitions, operating costs, and sales development.
Why is the level of liabilities of CureVac so important for investors?
The liabilities of CureVac are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.
What strategic measures can CureVac take to modify the liabilities?
To change its liabilities, CureVac can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.
How much dividend does CureVac pay?
Over the past 12 months, CureVac paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, CureVac is expected to pay a dividend of 0 EUR.
What is the dividend yield of CureVac?
The current dividend yield of CureVac is .
When does CureVac pay dividends?
CureVac pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of CureVac?
CureVac paid dividends every year for the past 0 years.
What is the dividend of CureVac?
For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.
In which sector is CureVac located?
CureVac is assigned to the 'Health' sector.
Wann musste ich die Aktien von CureVac kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of CureVac from 3/7/2025 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 3/7/2025.
When did CureVac pay the last dividend?
The last dividend was paid out on 3/7/2025.
What was the dividend of CureVac in the year 2024?
In the year 2024, CureVac distributed 0 EUR as dividends.
In which currency does CureVac pay out the dividend?
The dividends of CureVac are distributed in EUR.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The CureVac stock can be added to a savings plan with the following providers: Scalable Capital
Andere Kennzahlen von CureVac
Our stock analysis for CureVac Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of CureVac Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
